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Abstract
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome,
but many patients relapsed or become refractory to the available treatments. The main goal of the researchers in
CLL is the identification of specific targets in order to develop new therapeutic strategies to cure the disease. The B-
cell receptor-signalling pathway is necessary for survival of malignant B cells and its related molecules recently
become new targets for therapy. Moreover, leukemic microenvironment delivers survival signals to neoplastic cells
also overcoming the apoptotic effect induced by traditional drugs. In this context, the investigation of Bruton’s
tyrosine kinase (Btk) is useful in: i) dissecting CLL pathogenesis; ii) finding new therapeutic approaches striking
simultaneously intrinsic as well as extrinsic pro-survival signals in CLL. This paper will review these main topics.
Keywords: Chronic lymphocytic leukemia; Bruton’s tyrosine kinase;
Inhibitors; Therapy
Introduction to Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative
disease characterized by a progressive accumulation of CD19+/CD5+/
CD23+ B cells in the blood, bone marrow and lymphatic tissues. The
levels of surface immunoglobulins (Ig) and the expression of CD20 and
CD79b are characteristically low when compared with normal B cells.
Leukemic cells are restricted to the expression of either k or λ
immunoglobulin light chains. CLL is the most common leukemia in
western country, with an estimated incidence of 3-5 cases/100,000/
year. The median age at diagnosis is 72 years; however, almost 10% of
subjects have less than 55 years at disease onset [1,2]. The diagnosis of
CLL is established by the following the IWCLL-2008 criteria [3]: i) the
presence in the peripheral blood of ≥5,000 monoclonal B lymphocytes/
μl for at least 3 months with less than 55% of prolymphocytes; ii) the
clonality of circulating B lymphocytes as assessed by flow cytometry;
iii) the typical immunophenotype and iv) the features of leukemia cells
found in the blood smear which are small, mature lymphocytes with a
narrow border of cytoplasm and a dense nucleus lacking nucleoli and
with partially aggregated chromatin. The clinical heterogeneity
characterizing CLL, with survival time ranging from months to
decades reflects the biological diversity of the disease [4]. Researches
on the molecular pathogenesis of CLL allowed the identification of
differences in morphology, immunophenotype, specific chromosomal
abnormalities, aberrations in the B-cell receptor (BCR) signalling and
mutations of cancer related genes [5]. This biological heterogeneity
reflects the wide spectrum of clinical behaviours of the disease, ranging
from patients with a slow accumulation of leukemic cells to subjects
with rapidly increasing lymph nodes. Clinical markers include clinical
stage systems (Rai and Binet), lymphocyte doubling time (LDT) and
high levels of serum markers as LDH, beta-2 microglobulin and
thymidine kinase have been used to predicted tumor burden and
progression [6-10]. Anyway, the limit of these markers is the inability
to provide survival and treatment responses.
Cytogenetic alterations are the most important prognostic markers,
and among them deletions of 11q23, 13q14, 17p13 and trisomy 12 are
the most common. Deletions of 17p13 and/or TP53 mutations are
related to a very aggressive phenotype with low response to
conventional chemo-immunotherapies and, as consequence, are
recommended to direct treatment decision [3]. A well as recognized a
most relevant prognostic marker is represented by somatic
hypermutation of the IGHV genes. Presence of mutations, defined as
gene homology < 98% from the germline sequence, in the IGHV genes
is one of the most stable and reliable indicators of favorable clinical
outcome [11]. Several other prognostic markers have been identified
and, among them the most important are CD38, ZAP70 and CD49d;
however their use in clinical practice is still matter of controversy [3].
Some groups have tried to combine prognostic markers in order to
identify a reliable prognostic index; for example our group has recently
combined data of cytogenetic by FISH analysis, IGHV mutational
status and CD38 expression into the “Integrated CLL Scoring System”
[4]. In addition, recent reports on whole genome sequencing in CLL
have revealed a number of recurrent somatic gene mutations that
occur in parallel to the above-mentioned structural genomic
aberrations. These include the genes NOTCH1, MYD88, TP53, ATM,
SF3B1, FBXW7, POT1, CHD2, RPS15 and others [12-14]. The
accumulation of leukemic B cells results from a complex balance
between cell proliferation and apoptosis. In fact, CLL is not a static
disease simply resulting from the accumulation of long-lived
lymphocytes arrested in G0/G1 phases of cell cycle, but rather a disease
in which proliferative and accumulative pools coexist [15]. Important
advances in the molecular pathogenesis of CLL were obtained through
the study of structural and functional features of the BCR such as
IGHV mutations and deregulation of the BCR-dependent signaling
pathways. Several lines of evidence indicate that key molecules of the
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signaling pathway downstream BCR triggering are constitutively active
in CLL B cells, resulting in a ligand-independent BCR signaling,
defined as tonic signalling [16]; among them Lyn [17], Syk [18], PI3K
(phosphoinositide 3-kinase) [19,20] and mitogen-activated protein
kinase p38 [21] play the most important role. Aberrant miRNA
expression and DNA methylation have been also implicated in the
initiation and progression of CLL. Down-regulation of miR-15a/
miR-16-1, as consequence of 13q14 deletion, is implicated in the up-
regulation of BCL2 and thus blocking apoptosis [22]. The decrease of
miR-29c and miR-223 levels is reported to take place during the
progression of disease [23], whereas overexpression of miR-21 and
down-modulation of miR-181b are unfavorable prognostic markers
[24]. Interestingly, miR-18a and miR34a levels are correlated with a
shortened time to treatment and with TP53 status [25]. Finally,
aberrant methylation has been described for genes that are specifically
deregulated in CLL (i.e. TWIST-2, CD38, BTG4, HOXA4, DAPK1,
p16INK4a and p15INK4B. Interestingly, epigenetic regulation is likely
to have a role in altered miRNA expression in CLL [26]. Despite new
genetic prognostic markers and increasing discoveries on CLL
pathogenesis and progression, this disease is still incurable, although
readily controllable, with combination therapies, including purine
analogues, monoclonal antibodies, and newer targeted agents, such as
Btk inhibitors [27].
Brief Overview of Current Treatment Options and
Patient Outcomes
CLL is a slow-growing disease and most of patients do not require
treatment at diagnosis. The 2008 workshop on CLL provided specific
indications on which patients need treatment according to tumor
burden (LDT < 6 months and/or rapidly increasing lymphoid organs),
cytopenias and B symptoms. For these reasons, many subjects are only
“watched” until disease progression. The choice of specific treatment is
oriented on the basis of the number and kind of previous therapies
(first vs further lines, fludarabine refractory vs sensitive), fitness (fit vs
unfit vs frail patients) and on presence of TP53 abnormalities (17p
deletion and/or TP53 mutations) [28]. The gold standard treatment for
young (<65-70 years) and fit patients without TP53 abnormalities is
the chemo immunotherapy with rituximab-fludarabine-
cyclofosfamide (RFC). This regimen showed, for the first time, an
improvement of both progression free survival (PFS) and overall
survival (OS) [29]. However, RFC is too toxic for elderly unfit patients
in particular for the high-rate of infections; for this reason,
Bendamustine-Rituximab (BR) is considered a good alternative.
Preliminary result from CLL10 trial showed the superior efficacy of
RFC vs RB in previously untreated and physically fit patients with CLL
but not in the unfit elderly group, likely related to the higher number of
infective events [30]. Another international trial from the German
group, the CLL11 trial, showed a high response rate, an improved PFS
and secures toxicities profile of the combination chlorambucil (CLB)-
obinotuzumab vs. CLB-R vs. CLB alone [31]. Thanks to this study, the
combination of CLB with anti-CD20 antibody (obinotuzumab or R) is
considered the standard of untreated frail patients without TP53
abnormalites. Considering patients with TP53 abnormalities, both at
presentation and at relapse, the conventional regimens with chemo-
immunotherapies showed limited, if any, effects and short remissions.
For these reasons, these subjects should be treated within a clinical
trial, with BCR inhibitors or alentuzumab-containing regimens. For
young and fit patients with TP53 genetic lesions, allogenic stem cell
transplantation should also be considered balancing type of
transplantation (matched related or unrelated donor), condition
regiments (i.e. whether or not to use reduced-intensity regiments),
transplant-related mortality, graft versus host disease and
immunosuppressive therapy [28]. Patients, who relapsed after 24
months from the last therapy, can be retreated with the previous
regimens (i.e. RFC or RB). For those subjects who experienced
progression within 2 years since last treatment they should be recruited
in a clinical trial, or treated with BCR inhibitors, Ofatumumab or CLB
with anti-CD20. In particular, clinical trials investigating newer agents
should be considered for refractory patients. Refractoriness defined by
a disease progression within 6 months from the last treatment. Some
current ongoing studies are also investigating the role of a maintenance
therapy after induction chemotherapy in CLL [28]. For example, the
CLLM1 and the CLL002 continuum trials, from the CLL German
study group, are evaluating the efficacy/safety of Lenalidomide during
first and second remission, respectively. No data are available from
both studies and maintenance therapy is not recommended from
international guidelines. Nowadays, an increased number of new
compounds targeting impaired signaling pathways are in clinical
development and, of particular interest, are BCR signaling molecules.
Despite the pivotal role of Lyn and Syk in BCR signaling initiation, the
activity of their inhibitors (Dasatinib and Fostamatin, respectivily) in
clinical trial was only modest without long-lasting responses [28]. On
the other hand, the development of PI3K inhibitors (i.e. Idelalisib,
Duvelisib or Copanlisib), anti-BLC2 (i.e. Venetoclax) and Bruton’s
tyrosine kinase inhibitors (i.e. Ibrutinib and Acalabrutinib) are an
exciting field for biological researches and clinical applications [28].
Introduction to Btk-Known Physiological Functions
Bruton’s tyrosine kinase (Btk) is a non-receptor protein tyrosine
kinase belonging to the Tec family [32] and firstly identified in 1993
[33]. The protein consists of 659 amino acids for a molecular weight of
77 kDa and the BTK gene is located in the human X chromosome
(Xq21.3-22) [34]. BTK gene mutations result in a hereditary
immunodeficiency named X-linked agammaglobulinemia (XLA),
discovered by O.C. Bruton in 1952 [35,36] and characterized by the
lack of B lymphocytes development. Most of the Tec family kinases
(TFKs) (Figure 1), including Btk, are predominantly expressed in
hematopoietic cells with Btk absent in plasmacells and T lymphocytes
[32,37]. Like other TFKs, Btk contains different domains as illustrated
in Figure 2: a pleckstrin homology (PH), a Tec homology (TH), two
Src homology (SH) -3 and -2, which are all essential for the interaction
with other intracellular signaling proteins, and the catalytic domain.
TH domain is, in turn, composed of a region of homology between
GTPase activating protein (GAP), the Btk homology (BH) domain and
a proline-rich (PR) motif [37]. Following antigen ligation to BCR, the
Src family kinase (SFK) Lyn phosphorylates the immunoreceptor
tyrosine activation motifs (ITAMs) of CD79a and CD79b leading to
the activation of Syk, which in turn phosphorylates different
substrates. Among them, and and following BCR engagement, Btk
translocates to the plasma membrane, by the binding of the PH
domain to phosphatidylinositol 4,5-bisphosphate (PIP2), [38,39] where
it is phosphorylated at Tyr551 by Lyn. This event is followed by an
auto-phosphorylation at Tyr223 necessary for Btk full activation
[40,41]. As a consequence, and in tight cooperation with the adapter
protein B-cell linker (BLNK), Btk phosphorylates PLC-γ2 starting the
downstream signaling events. Following additional phosphorylation by
Syk, the adaptor protein SLP-65 functions as a scaffold for Btk and
PLCγ-2 that form a complex that initiates Calcium (Ca++) signaling.
Activated PLCγ-2 hydrolyzes membrane PIP2 into diacylglycerol
(DAG) and IP3, which binds to and activates IP3 receptors, through
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which Ca++ leaves the endoplasmic reticulum. In this context, the
fraction of Btk localized at the cell membrane positively regulates the
magnitude of Ca++ entry through calcium-release activated (CRAC)
channels following store depletion and this effect is blocked by protein
kinase Cβ (PKCβ) dependent phosphorylation of Btk. In fact, Btk is
also negatively regulated by PKCβ through phosphorylation at serine
(Ser) 180, resulting in an elegant mechanism of negative feedback [42].
Other proteins known to inhibit Btk activity are IBtk (inhibitor of Btk),
physically associated with it [43], and Sab (SH3BP5, SH3 domain-
binding protein 5) [44]. It has been demonstrated that also caveolin-1,
in B lymphocytes, functionally interacts with the kinase domain of Btk
leading to a drastic downregulation of Btk kinase activity [45]. Btk
plays a crucial role in B lymphocyte development, differentiation,
proliferation, signaling and survival [46]. Accordingly, B lymphocytes
lacking Btk do not reach the mature state and are probably condemned
to premature death. Individuals who have mutations in the gene
encoding Btk lack circulating mature B lymphocytes and serum
immunoglobulins of all isotypes thus being unable to mount a proper
immune response. This immunodeﬁciency is the previously mentioned
XLA [47]. When Btk is absent, B cell development is stopped between
the pro- and the pre-B-cell stages [48]. In addition to its role in BCR
signalling, Btk participates in the signal mediated by different others
surface receptors that regulate B lymphocytes-microenvironment
interactions (Figure 3). Btk takes part of α4β1 integrin signalling that
culminates in cytoskeletal reorganization [49], B cell migration and
tissue homing mediated by CXCL12-CXCR4 axis [50]. Moreover, Btk
is involved in the signalling mediated by different Toll-like receptors
(TLRs) and other crucial proteins belonging to these pathways thus
playing a prominent role in both the innate and adaptive immunity. In
particular, Btk, by targeting PLC-γ2 and IP-3, is required for IL-6
production in response to TLR9 and BCR activation and is necessary
for TLR9-BCR co-localization within an auto-phagosome-like
compartment [51]. In addition to B cells, defective functions related to
Btk have been detected in other cell types such as platelets and
macrophages [52,53] with impairments in macrophage polarization
[54]. The evidence that Btk is also present in the nucleus suggests its
involvement in transcriptional regulation. Btk, in fact, interacts with
different regulators of transcription by phosphorylating some of these
(i.e. NF-kB) and thus inducing their activity [55,56]. Btk has also been
shown to phosphorylate signal transducer and activator of
transcription 5A (STAT5A) in a B cell line [57].
Role of Btk in Chronic Lymphocytic Leukemia
In CLL, Btk protein expression is quite variable among patients and
apparently not correlated with patients’ clinical features. On the other
hand, Btk mRNA is signiﬁcantly higher in CLL with respect to normal
B cells showing no correlation with protein expression, thus suggesting
that the deregulation of Btk can take place at a post-transcriptional
level. Moreover, Western blotting analysis found a constitutive
phosphorylation of Btk, at basal conditions, in CLL cells varying
among patients [58]. Literature on Btk in CLL is mainly associated to
its inhibition by Ibrutinib (PCI-32765). These studies argue that Btk
inhibition sensitizes leukemic B cells to apoptosis and alters their
migratory activity. In fact, Ibrutinib exhibited a signiﬁcant dose-
dependent induction of cytotoxicity in CLL cells in a caspase-
dependent manner as demonstrated by induced PARP cleavage and
caspase-3 enzymatic activity [58]. Ibrutinib-induced apoptosis of
leukemic B cell uses a mechanism involving the inhibition of Lyn and
ERK kinases, two relevant proteins in CLL pathogenesis [59,60]. When
studying Btk in CLL, it must be taken into account that it is a Lyn
substrate after BCR engagement. In CLL, Lyn is overexpressed and
constitutively active [17], thus this molecule could modulate Btk
phosphorylation, and therefore its activity, with significant impact on
CLL B cell fate. NF-kB signaling is also down-modulated in CLL cells
from both the peripheral blood and tissue compartments during
Ibrutinib treatment [61]. These data demonstrate that Ibrutinib
effectively inhibits pathways that promote tumor cell activation and
proliferation. Moreover, secretion of CCL3 and CCL4 chemokines is
signiﬁcantly inhibited by Ibrutinib in CLL-nurse like cells (NLCs) co-
cultures, thus indirectly demonstrating the implication of Btk in the
connection of leukemic B cells with CLL microenvironment [62]. In
this context, Ibrutinib does not affect CLL B cell migration toward
conditioned medium of mesenchymal stromal cells (MSCs) isolated
from bone marrow (BM) of CLL patients, rich in cytokines and
chemokines, suggesting that neoplastic B cells do not lose their ability
to move toward a protective niche. In addition, during a co-culture of
CLL B cells with MSC, Ibrutinib is able to interfere with the expression
levels of chemokine receptors involved in cell migration and over-
expressed on CLL cells surface; in particular, Ibrutinib increase CXCR4
and decrease CXCR5 levels, while it does not affect CCR7 and CXCR3
expression [59,63]. Taking into account the importance of cell-cell
contact, it was demonstrated that Ibrutinib inhibits
pseudoemperipolesis in CLL B cells co-cultured with MSCs, a process
that involves the down-modulation of the integrin CD49d expression
[59]. This evidence suggests that Ibrutinib not only is able to reduce
CLL B cell viability by blocking key molecules for cell survival, but it
interferes with leukemic B clone-microenvironment interaction; this
aspect finds confirmation by the typical transient lymphocytosis
during Ibrutinib treatment due to the egress from the lymph nodes. In
this context, Baldari’s group and we demonstrated that Ibrutinib was
able to restore the expression of the cytokine receptor S1P1, which
plays a pivotal role in lymph node egress [63]. This finding, together
with a decrease in surface CXCR4 levels through the inhibition of
CXCR4 phosphorylation at Ser339 by Ibrutinib, results in the rapid
leukemic cell redistribution from secondary lymphoid organs to blood
[64].
Figure 1: Schematic representation of Tec family kinases. From
amino-terminal (NH2): PH (pleckstrin homology) or Cys
(Cysteine) domains, TH (Tec homology) which in turn is composed
by BH (Btk homology region) and/or PR (proline-rich region), SH3
(Src homology 3), SH2 (Src homology 2), and kinase domain at
carbossi-terminal region (COOH). Tec: tyrosine kinase expressed in
hepatocellular carcinoma; Btk: Bruton’s tyrosine kinase; Itk:
interleukin-2-inducible T-cell kinase; Bmx: bone marrow kinase in
chromosome X; Rlk: resting lymphocyte kinase.
Preclinical studies have shown that Ibrutinib effectively inhibits the
proliferation of malignant B lymphocytes and their survival in vivo, as
well as cell migration and adhesion to the substrate in vitro [65].
Results obtained in our lab (unpublished data), demonstrated that
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Ibrutinib is able to down-regulate both the expression and the
phosphorylation of Cortactin, a protein involved in CLL pathogenesis,
aggressiveness and migration [66].
Figure 2: Schematic representation of Btk structure. Btk consists of
different domains; from amino-terminal (NH2): PH (pleckstrin
homology), TH (Tec homology) which in turn is composed by
GH/BH (Btk homology region)/PR (proline-rich region), SH3 (Src
homology 3), SH2 (Src homology 2), and kinase domain at
carbossi-terminal region (COOH). Phosphorylation sites are
indicated in grey boxes (Ser21, Ser115, Ser180, Tyr223 and Tyr551);
Btk and Lyn phosphorylates Btk at Tyr223 and Tyr551 respectively
by activating it (green), PKCβ (protein kinase C β) phosphorylates
Btk at Ser180 by inhibiting it (red). Activators and inhibitors of Btk
are listed in the boxes green and red respectively. The diagram
shows Btk interacting proteins at its different domains.
Ser: serine; Tyr: tyrosine; SFKs: Src family kinases; Zn++: Zinc.
Figure 3: Representation of Btk involvement in different signaling
networks. A. BCR (B-cell receptor) signaling. B. Signaling from
chemokine/chemokine receptors interaction. C. Integrins-mediated
signaling. α4β1 is an integrin. D. Signaling from Toll-like receptors.
E. Btk activity into the nucleus. IL-6: Interleukein-6; IP3K:
Inositol-1,4,5-trisphosphate 3-kinase; PLCγ2: phospholipase C γ2;
BLNK: B-cell linker. SDF1α: stromal cell-derived factor 1; SFKs:
Src-family kinases; FAK: Focal adhesion kinase; TLR: Toll-like
receptor; Myd88: protein encoded by Myeloid differentiation
primary response gene 88; NF-kB: nuclear factor kappa B; NLC:
Nurse-like cell; MSC: Mesenchymal stromal cell.
Kil et al. [67] tempted to investigate Btk signaling in CLL
development, by modulating Btk expression in the EμTCL1 mouse
model. They demonstrated that CLL development is fully dependent
on Btk since in the Btk-deficient model they did not observe CLL
formation [67]. The importance of Btk in CLL has been confirmed by
Woyach et al. that come to the same conclusions by genetic
inactivation of Btk thus validating this molecule as a target for future
drug development [68].
Critical Analysis of the Clinical Potential for BTK
Inhibition in Chronic Lymphocytic Leukemia
Although therapies for CLL have shown a positive impact on
prognosis and clinical outcome, some patients relapse or become
unresponsive to treatment. Since several abnormalities of molecules
involved in different signal transduction pathways are connected to
CLL pathogenesis, the main goals of researchers in this field is the
identification and characterization of specific targets in order to
develop new therapeutic strategies to cure this malignancy. Taking into
account that the study of abnormalities in the signals mediated by BCR
is mandatory to deep into CLL pathogenesis, attention has increasingly
focused on BCR signaling molecules to be targeted. In CLL, the other
event contributing to the acquisition of the transformed phenotype
and the diffusion of the disease is the cross-talk between tumor cells
and the surrounding microenvironment. In fact, despite their in vivo
prolonged lifespan CLL leukemic cells rapidly undergo spontaneous
apoptosis when cultured in vitro, highlighting the need of signals
delivered by accessory cells, collectively referred as "the CLL
microenvironment", which modulate the apoptotic status of CLL cells
[69]. Leukemic cells co-cultured with different marrow adherent cell
types show greater survival, migration and drug resistance. The
targeting of these two events (intrinsic/BCR signaling and extrinsic/
microenvironment) has become increasingly urgent over the past year.
In this context, Btk is an ideal candidate because closely participates in
both BCR signaling and microenvironment-mediated events, thus
representing a great option to simultaneously target both intrinsic and
extrinsic pathogenic events leading to CLL. The recent attention,
focused on Btk inhibition, have provided a better knowledge of the
molecular and cellular mechanisms that lead to leukemic
transformation, designating Btk as a critical kinase at the cross-talk
between intrinsic and extrinsic survival mechanisms. At present,
different clinical trial with Btk inhibitors (PCI-32765/Ibrutinib alone
or in combinations, AVL-292, ACP-196 and ONO-4059) are under
investigation as detailed in Table 1.
O’Brien et al. [70] published the results of a phase Ib/II trial
(NCT01105247) which used Ibrutinib as initial therapy for elderly
previously untreated patients with CLL. Patients received 28-day cycles
of once-daily Ibrutinib 420 or 840 mg. The reported toxicity profile was
acceptable and 71% of the enrolled patients achieved an objective
response [70].
The international phase 3 RESONATETM trial compared Ibrutinib
420 mg once-day vs. Ofatumumab in relapsed refractory patients [71];
the primary end-point was PFS, while the duration of response rate
(RR) and OS were secondary end-points. At a median follow-up of 9.4
months, Ibrutinib significantly improved RR, PFS and OS as compared
with Ofatumumab. Similar effects were observed regardless of whether
patients had unmutated IGHV, 17p13 deletion or resistance to purine
analogs.
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MOLECULE(s) CT.gov IDENTIFIER PHASE SUBJECTS
R + B,
R + PCI-32765,
PCI-32765
NCT01886872 III Older patients with previously untreated CLL
LEN + PCI-32765 NCT01886859 I Relapsed/Refractory CLL
PCI-32765 + R vs. RFC NCT02048813 III Untreated CLL
PCI-32765 + OFA(1,2,3,4) NCT01217749 I Relapsed/Refractory CLL
PCI-32765(1,2,4) NCT01105247 I Older patients with previously untreated CLL
PCI-32765 vs. R NCT01973387 III Relapsed/Refractory CLL
PCI-32765 vs. OFA(2) NCT01578707 III Relapsed/Refractory CLL
PCI-32765 + RFC,
PCI-32765 + RB(1,2,4,5) NCT01292135 I CLL
PCI-32765 + RB NCT01611090 III Relapsed/Refractory CLL
PCI-32765(4,5) NCT01109069 II CLL
ACP-196 NCT02029443 I/II CLL
PCI-32765 NCT01589302 II Relapsed/Refractory CLL
PCI-32765 (2H20) NCT01752426 I/II CLL cells kinetics and trafficking, using heavy water labeling
AVL-292(1) NCT01351935 I Relapsed/Refractory CLL
CC-292 + LEN(4) NCT01732861 I CLL
CC-292 + R(4) NCT01744626 I CLL
ONO-4059 NCT01659255 I Relapsed/Refractory CLL
PCI-32765 NCT01500733 II Special CLL cases
GH/BH NCT02267590 I/II Tissue collection for biomarkers determining Ibrutinib resistance(CLARITY)
PCI-32765 NCT02556892 I Treatment-naive CLL
PCI-32765 + SEL NCT02303392 Relapsed/Refractory CLL
PCI-32765 + R + LENA NCT02160015 I Relapsed/Refractory CLL
PCI-32765 + OBI + GDC-0199 NCT02427451 I/II Relapsed/Refractory or previously untreated CLL
PCI-32765 + scF NCT02514083 II Previously untreated CLL
ACP196 + ACP319 NCT02157324 I Relapsed/Refractory CLL
DUV + OBI NCT02292225 I Previously treated CLL with BTK inhibitors (SYNCHRONY)
PCI-32765 + RFC NCT02251548 II Previously untreated, younger CLL patients
ACP-196 + PEM NCT02362035 I/II CLL
PCI-32765 and OFA + BMT or consolidation NCT02388048 II High Risk CLL
PCI-32765 vs. ACP-196 NCT02477696 III Previously treated with High Risk CLL
Table 1: Ongoing clinical trials using BTK inhibitors. 1completed; 2has results; 3efficacy; 4safety; 5tolerability.
CT.gov: ClinicalTrials.gov; R: Rituximab; B: Bendamustine; F: Fludarabine; C: Cyclophosphammide; LEN: Lenalidomide; OFA: Ofatumumab;
SEL: Selinexor; OBI: Obinutuzumab; PEM: Pembrolizumab (anti-PD1); ACP-196: Acalabrutinib; GDC-0199: Venetoclax; DUV: Duvelisib (anti-
PI3K); BMT: bone marrow transplant. http://www.clinicaltrials.gov
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Almost 20% of ibrutinib-treated patients showed a rapid decrease of
lymph nodes size together an increase of absolute lymphocyte count, a
condition, which has been called partial response with lymphocytosis.
51% of patients treated with Ibrutinib developed grade 3 or 4 adverse
events, as compared with 39% rate in the Ofatumumab group. The
most common were neutropenia (16% vs. 14%), pneumonia (7% vs.
5%) and diarrhea (4% vs. 2%). In addition, bleeding complications,
most commonly petechiae and ecchymoses, and atrial fibrillation were
more common in the Ibrutinib group (44% vs. 12% and 5% vs. 0.5%,
respectively). The durable responses and the low toxicity profile
observed with Ibrutinib, allows the majority of patients to receive
continuous therapy for an extended period. Byrd et al. [71] reported
long-term observation (median follow-up was 3 years) from 132
patients with symptomatic treatment-naive and relapsed/refractory
CLL or small lymphocytic lymphoma. Longer treatment with ibrutinib
was associated with improvement in the quality of response over time
and durable remissions. Toxicity with longer follow-up diminished
with respect to occurrence of hypertension, cytopenias, fatigue and
infections. Progression remains uncommon; however, they occurred
primarily in some patients with 17p13 or 11q23 deletion [72].
However, a work from MD Anderson Cancer Institute demonstrated
that a complex karyotype was a stronger predictor of outcomes from
Ibrutinib-treated patients than TP53 abnormalities; in fact, patients
with complex karyotypes had shorter PFS and OS [73]. Very recently,
Burger et al. reported results from the RESONATETM-2 indicating that
Ibrutinib was superior to CLB in previously untreated patients with
CLL/SLL, as assessed by RR (86% vs. 35%), PFS (rate at 18 months,
90% vs. 52%), OS (rate at 24 months, 98% vs. 85%). This study
established the role of oral-administered single-agent Ibrutinib as
initial treatment of elderly unfit patients with CLL [74]. Thanks to
these pivotal trials and strikingly results, Ibrutinib have recently
become world widely available. However, some patients developed
resistance to Ibrutinib. The mechanisms leading to resistance involved
mutations of BTK binding-site or of the downstream molecule PLCγ2.
A substitution of serine for cysteine at residue 481 (C481S) of BTK was
shown leading to the disruption of the Ibrutinib-BTK covalent
binding, changing irreversible to reversible binding. In this way, the
impaired binding leads to a loss of inhibition of BTK enzymatic
activity ultimately resulting in Ibrutinib resistance in the patient [75].
The R665W and L845F mutations in PLCγ2 are both potentially gain-
of-function mutations that lead to autonomous BCR activity regardless
upstream molecules inhibition [75]. The group of Rossi D. and
Gaidano G. provide evidence for the absence of these mutations in
Ibrutinib-naïve patients and their acquisition during the selective
pressure induced by Ibrutinib itself.
Several ongoing clinical trial are combining Ibrutinib with
traditional chemo-immunotherapy (R, FCR, BR, Obinotuzumab, etc.)
or investigating other more specific Btk inhibitors (AVL-292, ACP-196
and ONO-405; Table 1). The HELIOS trial was an international,
double-blind placebo-controlled, phase 3 study for CLL patients.
Patients were randomly assigned to receive RB with either Ibrutinib or
placebo. The primary end-point was PFS and crossover to Ibrutinib
was permitted for patients in the placebo group who experienced
progression. After a median follow-up of 17 months, PFS was
significantly improved in the Ibrutinib group compared with the
placebo group (not reached vs. 13.3 months, respectively). Grade 3 or
higher adverse events were similar in both arms. The conclusions of
authors were that in patients eligible for RB, the addition of Ibrutinib
results in significant improvements in outcome with a manageable
safety profile [76]. Hing et al. [77] have proposed to combine the XPO1
inhibitor Selinexor with Ibrutinib to overcome ibrutinib resistance.
The finding of new Btk specific inhibitors is mandatory considering
that the Ibrutinib concentrations, used in CLL, inhibit many other
protein tyrosine kinases, thus its anti-leukemic activity cannot be
completely ascribed to Btk inhibition alone [78]. In this context,
Acalabrutinib (ACP-196) is a more selective, irreversible BTK
inhibitor, specifically designed to improve the safety/efficacy of the
first-generation BTK inhibitors. Byrd et al. reported the results from
I/II phase multicenter study NCT02029443. Administration of twice-
daily Acalabrutinib, achieved a complete and continuous level of drug
binding to BTK, without inhibiting other kinases. Acalabrutinib
therapy showed a high RR, in particular in patients with 17p deletion it
was 100%, and durable remissions with a favorable safety [79].
Among other Btk inhibitors, AVL-292 (also named CC-292) is a
covalent highly selective orally active Btk inhibitor with IC50 of <0.5
nM, displaying at least 1400-fold selectivity over the other kinases
assayed, thus seem not appreciably inhibiting other kinases involved in
BCR signaling [80]. A Phase I escalating-dose completed trial
(NCT01351935) in subjects with relapsed or refractory B cell Non-
Hodgkin Lymphoma including CLL studied the use of AVL-292/
CC-292 monotherapy. Brown et al. [81] reported the first results at the
2013 ASH annual meeting showing that AVL-292/CC-292 was well
tolerated as an oral daily therapy being sufficient to achieve high nodal
and partial response rates in relapsed or refractory CLL patients,
including high-risk [81]. As regard ONO-4059, it is administered as
monotherapy in a Phase I clinical study in patients with relapsed or
refractory NHL and CLL. As reported by Salles et al. [82] responses
have occurred across all dose levels with patients experiencing
reductions in lymph nodes during the first cycle (28 days) of therapy.
An improvement in the hematological parameters occurred in all the
enrolled patients after at least 3 months of therapy with responses
observed in relapsed, refractory and 17p- patients [82]. At present,
Ibrutinib is also being tested in combination with more traditional
drugs in relapsed CLL patients. Burger et al. updated the results
obtained in a trial utilizing Ibrutinib combined with rituximab (14
months follow up) in high-risk CLL patients both treated and
untreated. 87% of the enrolled patients achieved partial remission and
8% complete remission. Despite some adverse events, treatment was
generally well tolerated, with infectious complications being the most
common [83]. Similar results have been reported for a trial including
Ibrutinib combined with R and B with a demonstrated safety profile
such of those obtained with BR containing regimen and Ibrutinib as
monotherapy. Also in this case, responses appeared to be independent
of high-risk features.
Concluding Remarks
Data so far collected from clinical studies involving the use of
Ibrutinib or other molecules inhibiting Btk, alone or in combination
with traditional therapies (ie: R, FLU, etc…), reported a good safety
profile and a high activity of the Btk inhibitors in CLL. Despite in the
last years chemo immunotherapy had considerably improved the
outcome of CLL patients, those having 17p deletion and/or TP53
mutations fail to respond to standard therapies and still represent an
unmet clinical need in the management of CLL. Btk inhibitors equally
affect patients with a good or poor prognosis, including those with 17p
deletion related to unfavorable prognosis. More generally, responses to
Ibrutinib were independent of high-risk clinical or genetic features. For
this reason, results from clinical trials demonstrated the efficacy and
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feasibility of Btk inhibitors for all patients with CLL, irrespective of
prognostic factors. In some cases, questionnaires proposed during the
clinical studies, revealed a significantly improved overall health and
quality of life after 6 months of treatment (R + Ibrutinib). Since CLL is
mainly a disease of the elderly, this type of therapy would help in
reducing disability to cancer. In this context, several new molecules,
which target key elements in leukemic cell survival, are entering
clinical practice, alone or in association to standard therapies, with the
ultimate goal to tailor therapy in each patient. This will optimize the
efficiency and effectiveness of health care. Overall data obtained in
these studies, despite some of them are still preliminary, seem to
encourage and promote the enrollment of refractory/relapsed CLL
patients in those protocols involving the using of Btk inhibitors.
Further, these data support the hypothesis of a first-line treatment with
Btk inhibitors for those patients with high genomic risk.
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